Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform
Published . Updated .
Fintel reports that on September 23, 2026, Oppenheimer initiated coverage of Amneal Pharmaceuticals (NASDAQGS:AMRX) (DB:2DT) with a Outperform recommendation.Amneal Pharmaceuticals, Inc., based in the United States, operates primarily in the generic and specialty pharmaceutical s
Directly affected
- AMRX Amneal Pharmaceuticals
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Fintel reports that on September 23, 2026, Oppenheimer initiated coverage of Amneal Pharmaceuticals (NASDAQGS:AMRX) (DB:2DT) with a Outperform recommendation.Amneal Pharmaceuticals, Inc., based in the United States, operates primarily in t…
Source: Nasdaq Markets
How far Amneal Pharmaceuticals (AMRX) has moved since 24 Sep 2026
Since the first closing price after “Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform,” Amneal Pharmaceuticals (AMRX) is -2.00%. The S&P 500 fund (SPY) is -0.62% over the same days, a -1.38% difference versus the market.
Who reported a Amneal Pharmaceuticals (AMRX) trade near this story
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 5 days after publication, inside 30 days. The filing is listed beside the story “Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 13 days before publication, inside 30 days. The filing is listed beside the story “Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 52 days before publication, inside 60 days. The filing is listed beside the story “Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 56 days before publication, inside 60 days. The filing is listed beside the story “Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 56 days before publication, inside 60 days. The filing is listed beside the story “Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Amneal Pharmaceuticals (AMRX)
Companies carried with this story
- AMRX Amneal Pharmaceuticals
For “Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform,” Amneal Pharmaceuticals (AMRX) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names AMNEAL PHARMACEUTICALS INC in the headline; GA resolved that company to AMRX
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform.” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
Davita (DVA) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform.” Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform.” Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Amneal Pharmaceuticals (AMRX)
On 24 Sep 2026, “Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform” is the story that connects Amneal Pharmaceuticals (AMRX) to this story.
Amneal Pharmaceuticals (AMRX) is on the page because The reported development directly names AMNEAL PHARMACEUTICALS INC in the headline; GA resolved that company to AMRX
A second company, Acadia Healthcare (ACHC), is listed for a different reason: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for Amneal Pharmaceuticals (AMRX)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. AMRX traded between 16.58 and 20.78 across 20 sessions. The latest close on file is 19.37. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99.
How strong the case is around Amneal Pharmaceuticals (AMRX)
46 out of 100
“Oppenheimer Initiates Coverage of Amneal Pharmaceuticals at Outperform” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.